Journal
CARDIOLOGY CLINICS
Volume 34, Issue 3, Pages 375-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2016.04.006
Keywords
Pulmonary arterial hypertension; Echocardiography; Right heart catheterization; Prostacyclin; Phosphodiesterase inhibitor; Endothelin antagonist
Categories
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is a specific, rare disease characterized by a well-described pattern of pulmonary vascular remodeling. The elevated pulmonary artery pressure in PAH results in increased right ventricular afterload, which, if untreated, leads rapidly to right ventricular failure and death. Recent marked expansion in knowledge about PAH has resulted in the development of effective therapies that improve quality of life and survival. However, delays in diagnosis and suboptimal treatment remain significant barriers to achieving optimal patient outcomes. Continued success in raising PAH awareness, earlier diagnosis, and the availability of new therapies mean a promising future for PAH patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available